Inorganic Pyrophosphate Homeostasis (PPi) in Pediatric Chronic Kidney Disease
The investigator aim to identify the role of inorganic pyrophosphate and other anti-calcifying molecules in vascular disease in children with chronic kidney disease, with a view to developing therapeutic approaches aimed at limiting the onset of vasculopathy.
- EligibilityCriteria: Inclusion Criteria:  All groups :  Minor patients (<18 years) Patients of both sexes Informed patients and parents who have signed the informed consent form Patients affiliated to social security  Control group :  - Patients with no particular pathology undergoing surgery and receiving a preoperative check-up  CKD groups :  Patients on dialysis for more than 3 months, regardless of technique Kidney transplant patients Patients with CKD, whatever the cause  Exclusion Criteria:  Progressive cancer or kidney disease Treatments that may modify PPi concentration (e.g. bisphosphonates) - HealthyVolunteers: No - Gender: All - MinimumAge: 0 Years - MaximumAge: 18 Years - StdAgeList: Child, Adult